Multiple Myeloma
The Multiple Myeloma pipeline: 154 tracked drugs, 22 approved for this indication.
22 approved / phase 428 Phase 38 Phase 233 Phase 1/247 Phase 11 US approval withdrawn15 preclinical / unstaged
Compare the share prices of listed companies in Multiple Myeloma →
Total attributable cost
$11.1B
$54,968/patient
Drug spend
Not yet sourced
All stages, prevalent population (2023 SEER estimate) · US
The Multiple Myeloma pipeline
Key trial results for every approved and late-stage drug: Multiple Myeloma results by drug.